We fight to improve the lives
of everyone affected by epilepsy

Lacosamide epilepsy medicine approved for use in children over 4 years old with focal-onset seizures

29 Sep 2017

Pharmaceutical company UCB’s lacosamide epilepsy medicine, known as VIMPAT, has been approved by the European Commission for use in children over 4 years old in Europe.

The lacosamide medicine was approved in September for use on its own or alongside other medicines to treat focal-onset seizures. It was previously approved for use in teenagers over 16 years old and adults in Europe.

Jeff Wren, executive vice president of UCB, said: “[The] approval of lacosamide for children aged 4 to 16 is an important step forward for the management of paediatric epilepsy, a condition which can present significant challenges to children and their families.”

The European Medicines Agency had previously found that focal epilepsy in children over 4 years old is similar to that in adults. According to UCB, the approval of their lacosamide medicine was based on data on its effectiveness in adults and safety data in children.

The company added that children with epilepsy may experience side-effects from the medicines currently available for this type of epilepsy. They also added that around 10-29% of children with epilepsy don’t have seizure control with the medicines available at the moment. UCB concluded that this means there is a need for more and new treatment options to help control seizures in children and avoid side-effects.


You may also be interested in…

Royal College of Paediatrics and Child Health starts next Epilepsy12 audit into children’s epilepsy services

The Royal College of Paediatrics and Child Health (RCPCH) is starting a new review into how effective children’s epilepsy services are. This is known as the Epilepsy12 audit and this is the third review of this kind.

There are no comments yet. Be the first to comment...

Question about your epilepsy?

Your question will be sent to our helpline advisors.

Have a comment about this page?

All comments are reviewed by a moderator before publishing. Comments will be edited or deleted if they are offensive, libellous, slanderous, abusive, commercial or irrelevant.

We ask for your email when you make a comment through this website. This means that we can let you know directly that we have replied to you. By making a comment through the website, you allow us to use the comment in our publicity without using your name. If we would like to use your name, we will email you to get your permission.

The content of this field is kept private and will not be shown publicly.
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
15 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.